Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-24
    E.g., 2018-09-24

Articles

173342 items
10:36 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Other News

Roivant launches respiratory vant, announces other vant news

Roivant Sciences GmbH (Basel, Switzerland) announced the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp. (Waltham, Mass.), and its...
10:36 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Regulatory

FDA approves Teva's Ajovy, second CGRP inhibitor to prevent migraine

FDA approved Ajovy fremanezumab-vfrm from Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) on Sept. 14 to prevent migraine in adults. The mAb targeting the calcitonin gene-related peptide ligand is the second in its class approved...
9:44 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Histogenics' NeoCart misses in Phase III for knee cartilage repair

Histogenics Corp. (NASDAQ:HSGX) said NeoCart missed the primary endpoint of improving pain and function at one year in a Phase III trial to repair knee cartilage damage. The company said the product narrowly missed the...
9:43 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Other News

Clovis settling SEC complaint for $20M

The SEC said Clovis Oncology Inc. (NASDAQ:CLVS) will pay more than $20 million in penalties to settle charges that it misled investors about the efficacy of discontinued lung cancer candidate rociletinib. According to SEC's complaint, Clovis...
9:43 AM, Sep 21, 2018  |  BC Week In Review | Company News  |  Deals

Atomwise identifying small molecules for Pfizer

Atomwise Inc. (San Francisco, Calif.) partnered with Pfizer Inc. (NYSE:PFE) to use its AI platform to identify small molecule candidates for up to three target proteins from Pfizer. Atomwise will receive an undisclosed technology access...
9:43 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with alpha fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) in a...
9:42 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

BioCryst's oral HAE candidate reduces attack symptom severity in Phase II

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) reported data from 33 evaluable patients treated for a total of 95 acute attacks of hereditary angioedema (HAE) in the Phase II ZENITH-1 trial showing that a single 750 mg dose...
9:42 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

AZ says Phase IIIb data of Bevespi Aerosphere in COPD are 'inconsistent with previous data'

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Bevespi Aerosphere glycopyrrolate/formoterol fumarate met one of three primary endpoints in the Phase IIIb AERISTO trial to treat moderate to very severe chronic obstructive pulmonary disease (COPD). Bevespi Aerosphere was...
9:42 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Nucleix's Lung EpiCheck detects lung cancer with 91% specificity, 74% sensitivity

Nucleix Ltd. (Rehovot, Israel) said its Lung EpiCheck blood test showed 91% specificity and 74% sensitivity for the early detection of lung cancer in a cohort of 181 lung cancer patients and 141 current or...
9:42 AM, Sep 21, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Filgotinib meets in Phase II for ankylosing spondylitis

Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported that once-daily 200 mg oral filgotinib met the primary endpoint of reducing mean Ankylosing Spondylitis Disease Activity Score (ASDAS) from baseline to week 12 vs....

Pages